| Cost-effectiveness of disease-modifying therapy for multiple sclerosis: A population-based study. | |
| | |
MedLine Citation:
|
PMID: 21775734 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
OBJECTIVE: To evaluate the cost-effectiveness of disease-modifying therapies (DMTs) in the United States compared to basic supportive therapy without DMT for patients with relapsing multiple sclerosis (MS). METHODS: Using data from a longitudinal MS survey, we generated 10-year disease progression paths for an MS cohort. We used first-order annual Markov models to estimate transitional probabilities. Costs associated with losses of employment were obtained from the Bureau of Labor Statistics. Medical costs were estimated using the Centers for Medicare and Medicaid Services reimbursement rates and other sources. Outcomes were measured as gains in quality-adjusted life-years (QALY) and relapse-free years. Monte Carlo simulations, resampling methods, and sensitivity analyses were conducted to evaluate model uncertainty. RESULTS: Using DMT for 10 years resulted in modest health gains for all DMTs compared to treatment without DMT (0.082 QALY or <1 quality-adjusted month gain for glatiramer acetate, and 0.126-0.192 QALY gain for interferons). The cost-effectiveness of all DMTs far exceeded $800,000/QALY. Reducing the cost of DMTs had by far the greatest impact on the cost-effectiveness of these treatments (e.g., cost reduction by 67% would improve the probability of Avonex being cost-effective at $164,000/QALY to 50%). Compared to treating patients with all levels of disease, starting DMT earlier was associated with a lower (more favorable) incremental cost-effectiveness ratio compared to initiating treatment at any disease state. CONCLUSION: Use of DMT in MS results in health gains that come at a very high cost. |
| | |
Authors:
|
K Noyes; A Bajorska; A Chappel; S R Schwid; L R Mehta; B Weinstock-Guttman; R G Holloway; A W Dick |
Related Documents
:
|
9571114 - Internet technology in magnetic resonance: a common gateway interface program for the w... 21813034 - A systematic review of the cost-effectiveness of interventions for supporting informal ... 15941124 - Perceived gender of a pastor's name and ratings of vocational success. 3746904 - The effects of behavioral vision training on multiple aspects of visual functioning in ... 21780734 - Improving feedback to students online: teaching tips from experienced faculty. 6851384 - A new obstetric unit. e. h. crump women's hospital and perinatal center, memphis, tenne... |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2011-7-20 |
Journal Detail:
|
Title: Neurology Volume: - ISSN: 1526-632X ISO Abbreviation: - Publication Date: 2011 Jul |
Date Detail:
|
Created Date: 2011-7-21 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0401060 Medline TA: Neurology Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Affiliation:
|
From the Departments of Community and Preventive Medicine (K.N., A.B., A.C.) and Neurology (S.R.S., R.G.H.), University of Rochester, Rochester, NY; Evergreen Neuroscience Institute (L.R.M.), Kirkland, WA; Jacobs Neurological Institute (B.W.-G.), SUNY University at Buffalo, Buffalo, NY; and Rand Corporation (A.W.D.), Pittsburgh, PA. Dr. Chappel is now at the Office of the Assistant Secretary for Planning and Evaluation, HSD HHS, Washington, DC. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Progressive encephalomyelitis with rigidity and myoclonus: glycine and NMDA receptor antibodies.
Next Document: Contrast-free MRA at 3.0 T for the detection of intracranial aneurysms.